Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
BMJ Open|January 30, 2026
Breathing control training as a treatment for functional seizures (BREATHS trial): a multicentre, assessor-blinded, randomised controlled efficacy and acceptability trial study protocolRichard Kanaan, Rod Duncan, Cathrine Mihalopoulos, et al.
The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Haematologica|September 17, 2016
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantationGordon Cook, Simona Iacobelli, Anja van Biezen, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Brain Communications|June 27, 2022
Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulationVladimir Sladky, Petr Nejedly, Filip Mivalt, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Pageof 19